Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan, Takeda Launch Enbrel New Pen Preparation
June 12, 2013
- Otsuka Chosen by METI as Model Enterprise for Efforts to Ensure Stable Drug Supplies During Emergencies
June 11, 2013
- R&D Operations Start for Diagnostic Products: Alfresa Pharma
June 11, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
June 11, 2013
- Ethical, OTC Drug Sales Up 1.3% and 9.5%: Crecon Report
June 10, 2013
- Bayer to File Eylea for mCNV in Japan Later This Year
June 10, 2013
- Taiho’s TS-1 Non-Inferior to UFT/LV in Resected Colon Cancer Patients: PIII Study
June 7, 2013
- Nichi-Iko Announces Launching of Authorized Generic of Allegra in June; Is Late Launch Part of Sanofi’s Carefully Worked-out Strategy?
June 7, 2013
- Use of Contract MRs on the Rise among Smaller Drug Makers; JCSOA’s Goal of “5,000 CMRs by 2015” May Be Realistic
June 7, 2013
- Zeria, Astellas Launch World’s First FD Treatment
June 6, 2013
- DSP Completes Construction of New Chemical Research Facility in Osaka
June 6, 2013
- AZ Decides Not to Proceed with Regulatory Filings for Novel Oral RA Treatment Fostamatinib
June 6, 2013
- Nihon Chouzai to Increase Its Subsidiary’s Generic Production Capacity
June 5, 2013
- Takeda Unveils Interim Data from ADCETRIS PI Study in Pediatric Patients
June 5, 2013
- Fujifilm, Dr. Reddy’s Terminate Plan for Joint Venture for Generics
June 5, 2013
- Novartis Pharma to Cut Pay of 9 Top Officials and Suspend Promotion of Ethical Drugs for 5 Days Over Diovan Scandal
June 5, 2013
- Nippon Chemiphar to Outsource Production to Vietnam Next Spring
June 5, 2013
- BMKK, Ono Start Copromotion of Orencia following Lifting of All-Case Surveillance
June 5, 2013
- Four Drug Makers File Their Anticancer Drugs for FOLFIRINOX Therapy for Pancreatic Cancer
June 4, 2013
- Japan Pharma Leaders: Drug Development via GHIT Fund Hoped to Fuel Economic Growth in Developing World
June 4, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…